All In Biotech

Drug Trial Radar · NCT07227402

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 904 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

904

Planned (sponsor's estimate)

Start

Nov 26, 2025

Primary completion

Feb 27, 2032

Study completion Mar 21, 2033

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Exelixis
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

Conditions

  • Renal Cell Carcinoma

Interventions

  • BelzutifanDrug

    Administered orally QD

  • ZanzalintinibDrug

    Administered orally QD

  • CabozantinibDrug

    Administered orally QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 73 months
  2. Overall Survival (OS)Time frame: Up to approximately 73 months

Locations

129 sites in 24 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology ( Site 0133)

    Anchorage, Alaska · Recruiting

  • Providence Medical Foundation ( Site 0141)

    Fullerton, California · Recruiting

  • USC Norris Comprehensive Cancer Center ( Site 0126)

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center ( Site 0112)

    Los Angeles, California · Recruiting

  • New England Cancer Specialists ( Site 0132)

    Westbrook, Maine · Recruiting

  • Greater Baltimore Medical Center ( Site 0145)

    Baltimore, Maryland · Recruiting

  • Metro-Minnesota Community Clinical Oncology ( Site 0144)

    Saint Louis Park, Minnesota · Recruiting

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131)

    Omaha, Nebraska · Recruiting

  • Carolina Oncology Specialists, PA ( Site 9002)

    Charlotte, North Carolina · Recruiting

  • Thompson Cancer Survival Center ( Site 0125)

    Knoxville, Tennessee · Recruiting

  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)

    Nashville, Tennessee · Recruiting

  • Hospital Privado Universitario de Córdoba ( Site 0207)

    Córdoba, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires. ( Site 0203)

    Caba, Buenos Aires, Argentina · Recruiting

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205)

    Caba, Buenos Aires, Argentina · Recruiting

  • Hospital Aleman ( Site 0204)

    CABA, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0202)

    CABA, Buenos Aires, Argentina · Recruiting

  • Hospital Universitario Austral ( Site 0212)

    Pilar, Buenos Aires, Argentina · Recruiting

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0208)

    Caba., Buenos Aires F.D., Argentina · Recruiting

  • Sanatorio Parque ( Site 0201)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Instituto de Oncología de Rosario ( Site 0209)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 2100)

    Sydney, New South Wales, Australia · Recruiting

  • Medizinische Universitat Wien ( Site 0601)

    Vienna, Austria · Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0600)

    Linz, Upper Austria, Austria · Recruiting

  • Cliniques Universitaires Saint-Luc ( Site 0703)

    Brussels, Bruxelles-Capitale, Region de, Belgium · Recruiting

  • Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 0701)

    Genk, Limburg, Belgium · Recruiting

  • UZ Gent ( Site 0702)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • UZ Leuven ( Site 0700)

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • IPC - MT Instituto de Pesquisas Clínicas do Mato Grosso ( Site 0305)

    Cuiabá, Mato Grosso, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 0307)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital Moinhos de Vento ( Site 0309)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Hospital Alemao Oswaldo Cruz ( Site 0311)

    São Paulo, São Paulo, Brazil · Recruiting

  • Oncocentro Valdivia ( Site 0408)

    Valdivia, Los Ríos Region, Chile · Recruiting

  • Fundacion Arturo Lopez Perez ( Site 0401)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Investigacion Clinica UC CICUC ( Site 0402)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Klinički bolnički centar Sestre milosrdnice ( Site 0801)

    Zagreb, City of Zagreb, Croatia · Recruiting

  • Klinički bolnički centar Zagreb ( Site 0800)

    Zagreb, City of Zagreb, Croatia · Recruiting

  • Klinički Bolnički Centar Split ( Site 0802)

    Split, Split-Dalmatia County, Croatia · Recruiting

  • Nemocnice České Budějovice ( Site 0905)

    České Budějovice, Czechia · Recruiting

  • Fakultni nemocnice Hradec Kralove ( Site 0902)

    Hradec Králové, Czechia · Recruiting

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.